Vanguard Group’s Endocyte, Inc. Common Stock ECYT Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2018
Q4 | – | Sell |
-3,524,390
| Closed | -$62.6M | – | 4172 |
|
2018
Q3 | $62.6M | Buy |
3,524,390
+394,259
| +13% | +$7M | ﹤0.01% | 2039 |
|
2018
Q2 | $43.2M | Buy |
3,130,131
+750,967
| +32% | +$10.4M | ﹤0.01% | 2195 |
|
2018
Q1 | $21.6M | Buy |
2,379,164
+749,755
| +46% | +$6.82M | ﹤0.01% | 2464 |
|
2017
Q4 | $6.97M | Buy |
1,629,409
+127,562
| +8% | +$546K | ﹤0.01% | 2996 |
|
2017
Q3 | $2.12M | Buy |
1,501,847
+174,550
| +13% | +$246K | ﹤0.01% | 3380 |
|
2017
Q2 | $1.99M | Sell |
1,327,297
-302,539
| -19% | -$454K | ﹤0.01% | 3382 |
|
2017
Q1 | $4.19M | Buy |
1,629,836
+143,497
| +10% | +$369K | ﹤0.01% | 3127 |
|
2016
Q4 | $3.79M | Buy |
1,486,339
+32,961
| +2% | +$84.1K | ﹤0.01% | 3158 |
|
2016
Q3 | $4.49M | Buy |
1,453,378
+156,960
| +12% | +$485K | ﹤0.01% | 3057 |
|
2016
Q2 | $4.16M | Buy |
1,296,418
+6,144
| +0.5% | +$19.7K | ﹤0.01% | 3070 |
|
2016
Q1 | $4M | Buy |
1,290,274
+59,015
| +5% | +$183K | ﹤0.01% | 3078 |
|
2015
Q4 | $4.94M | Buy |
1,231,259
+21,788
| +2% | +$87.4K | ﹤0.01% | 2988 |
|
2015
Q3 | $5.54M | Buy |
1,209,471
+53,522
| +5% | +$245K | ﹤0.01% | 2918 |
|
2015
Q2 | $6M | Buy |
1,155,949
+78,723
| +7% | +$409K | ﹤0.01% | 2921 |
|
2015
Q1 | $6.74M | Buy |
1,077,226
+55,842
| +5% | +$350K | ﹤0.01% | 2841 |
|
2014
Q4 | $6.42M | Buy |
1,021,384
+24,795
| +2% | +$156K | ﹤0.01% | 2763 |
|
2014
Q3 | $6.06M | Sell |
996,589
-35,655
| -3% | -$217K | ﹤0.01% | 2732 |
|
2014
Q2 | $6.8M | Buy |
1,032,244
+19,060
| +2% | +$126K | ﹤0.01% | 2694 |
|
2014
Q1 | $24.1M | Buy |
1,013,184
+121,680
| +14% | +$2.9M | ﹤0.01% | 2123 |
|
2013
Q4 | $9.53M | Sell |
891,504
-22,073
| -2% | -$236K | ﹤0.01% | 2489 |
|
2013
Q3 | $12.2M | Buy |
913,577
+39,298
| +4% | +$524K | ﹤0.01% | 2304 |
|
2013
Q2 | $11.5M | Buy |
+874,279
| New | +$11.5M | ﹤0.01% | 2274 |
|